Search results
Results from the WOW.Com Content Network
NVAX data by YCharts. Novavax's late-stage trials hit a snag. Novavax successfully developed a COVID-19 vaccine that is currently its only product on the market. The company has been working on ...
One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent years due to its COVID-19 vaccine and pill (its revenue topped $100 ...
Kennedy has long railed against vaccines, once calling those that protect against Covid-19 a "crime against humanity." He has treaded more carefully in recent weeks, though, and has said he wouldn ...
An hour before the market closed Thursday, as news reports of Trump’s choice began trickling out, Covid-19 vaccine maker Moderna dipped as much as 6%, and Pfizer fell almost 2%.
The company generated billions of dollars in revenue thanks to its coronavirus vaccine and treatment, even reaching a record of more than $100 billion in total company revenue in 2022.
Shares of vaccine stocks Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and BioNTech SE (NASDAQ: BNTX) rallied this week, appreciating 23.4%, 16.4%, and 9.3%, respectively, through Thursday ...
COVID-19 vaccines gave Moderna, Pfizer and Johnson & Johnson a boost — but are their stocks still good buys in 2021? Here's what to consider before investing.
As the omicron variant picks up speed, investors are turning to vaccine stocks that could potentially profit. The U.S. is currently averaging 121,107 new Covid-19 cases per day and showing no ...